NO20060123L - Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi - Google Patents

Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Info

Publication number
NO20060123L
NO20060123L NO20060123A NO20060123A NO20060123L NO 20060123 L NO20060123 L NO 20060123L NO 20060123 A NO20060123 A NO 20060123A NO 20060123 A NO20060123 A NO 20060123A NO 20060123 L NO20060123 L NO 20060123L
Authority
NO
Norway
Prior art keywords
cancer
disorder
steroid hormone
uterine
type
Prior art date
Application number
NO20060123A
Other languages
English (en)
Inventor
Leena Hirvela
Nina Johansson
Pasi Koskimies
Olli Taneli Pentikainen
Tommi Nyronen
Tiina Annamaria Salminen
Mark Stuart Johnson
Pekka Lehtovuori
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20060123L publication Critical patent/NO20060123L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Joining Of Glass To Other Materials (AREA)

Abstract

Denne oppfinnelsen vedrører benzo(4,5)tieno(2,3-d)pyrimidin-4-on-forbindelser, deres 5,6-dihydro- og 5,6,7,8tetrahydroderivater, og deres anvendelse til behandlingen av en steroidhormonavhengig sykdom eller forstyrrelse, fortrinnsvis for en steroidhormonavhengig sykdom eller forstyrrelse som krever inhiberingen av et 17ß-hydroksysteroiddehydrogenaseenzym, mest foretrukket enzymet 17beta-HSD type 1, type 2 eller type 3. Den steroidhormon- avhengige sykdom eller forstyrrelse er valgt fra gruppen bestående av brystkreft, prostatakarsinom, eggstokkreft, livmorkreft, endometriumkreft og endometriumhyperplasi, endometriose, livmorfibroider, livmorleiomyom, adenomyose, dysmenoré, menoragi, metroragi, prostadyni, godartet prostatahyperplasi, prostatitt, akne, seborré, hirsutisme, androgen alopesi, for tidlig pubertet, adrenalhyperplasi, polycystisk ovariesyndrom, urinveisdysfunksjon, osteoporose, multippel sklerose, reumatoid artritt, Alzheimers sykdom, tykktarmskreft, vevssår, hudrynker og katarakter.
NO20060123A 2003-06-10 2006-01-09 Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi NO20060123L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47704703P 2003-06-10 2003-06-10
PCT/EP2004/006230 WO2005032527A2 (en) 2003-06-10 2004-06-09 Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy

Publications (1)

Publication Number Publication Date
NO20060123L true NO20060123L (no) 2006-03-09

Family

ID=34421462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060123A NO20060123L (no) 2003-06-10 2006-01-09 Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Country Status (24)

Country Link
US (1) US7465739B2 (no)
EP (1) EP1635839B1 (no)
JP (1) JP4605800B2 (no)
KR (1) KR20060054189A (no)
CN (1) CN1791412A (no)
AR (1) AR044650A1 (no)
AT (1) ATE479437T1 (no)
AU (1) AU2004277311B8 (no)
BR (1) BRPI0411295A (no)
CA (1) CA2527617A1 (no)
DE (1) DE602004028934D1 (no)
DK (1) DK1635839T3 (no)
ES (2) ES2352552T3 (no)
IL (1) IL172316A0 (no)
MX (1) MXPA05012745A (no)
NO (1) NO20060123L (no)
PL (1) PL1635839T3 (no)
PT (1) PT1635839E (no)
RU (1) RU2412190C2 (no)
SA (1) SA04250159B1 (no)
SI (1) SI1635839T1 (no)
TW (1) TWI349551B (no)
WO (1) WO2005032527A2 (no)
ZA (1) ZA200508296B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
JP2007536239A (ja) * 2004-05-06 2007-12-13 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
EP1802634A2 (en) * 2004-10-20 2007-07-04 Compass Pharmaceuticals LLC Thiophens and their use as anti-tumor agents
AU2004325692B2 (en) * 2004-12-13 2012-01-19 Solvay Pharmaceuticals Gmbh Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase
FR2904000A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
BRPI0923126A2 (pt) 2008-12-23 2021-09-08 President And Fellows Of Harvard College Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
CN105518017B (zh) 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
WO2014207310A1 (en) 2013-06-25 2014-12-31 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド １７β−ＨＳＤ１−阻害剤のプロドラッグ
EP3237430B1 (en) 2014-12-23 2019-03-20 Forendo Pharma Ltd PRODRUGS OF 17ß -HSD1 -INHIBITORS
WO2017075694A1 (en) * 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
JP7064515B2 (ja) 2017-06-08 2022-05-10 フォレンド ファーマ リミテッド １５β－［３－プロパンアミド］－置換エストラ－１，３，５（１０）－トリエン－１７－オン化合物および１７β－ヒドロキシステロイドデヒドロゲナ－ゼの阻害に使用するためのそれらの１７－オキシム
CN109503572B (zh) * 2017-09-15 2021-10-08 上海交通大学 一种合成吲哚喹啉类化合物的方法
BR112021010598A2 (pt) 2018-12-05 2021-08-24 Forendo Pharma Ltd Compostos, método para preparação de um composto e composição farmacêutica
US20230416268A1 (en) * 2022-04-28 2023-12-28 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (no) * 1968-06-20 1972-10-25
US3775027A (en) 1971-10-01 1973-11-27 Gray Manuf Co Inc Two-speed pump
JPS62132884A (ja) 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
AU9001698A (en) 1997-09-11 1999-03-29 Snow Brand Milk Products Co., Ltd. Remedies for hormone-dependent diseases
BR9908592A (pt) * 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
ATE355279T1 (de) 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
EP1326829A2 (en) 2000-09-29 2003-07-16 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
EP1423381B1 (en) 2001-09-06 2007-01-03 Schering Corporation 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6750248B2 (en) * 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

Also Published As

Publication number Publication date
WO2005032527A2 (en) 2005-04-14
RU2412190C2 (ru) 2011-02-20
AU2004277311A1 (en) 2005-04-14
ATE479437T1 (de) 2010-09-15
SI1635839T1 (sl) 2010-12-31
PT1635839E (pt) 2010-10-12
EP1635839B1 (en) 2010-09-01
US7465739B2 (en) 2008-12-16
ES2352554T3 (es) 2011-02-21
ZA200508296B (en) 2007-01-31
ES2352552T3 (es) 2011-02-21
TW200509937A (en) 2005-03-16
TWI349551B (en) 2011-10-01
AR044650A1 (es) 2005-09-21
AU2004277311B8 (en) 2010-05-27
WO2005032527A3 (en) 2005-08-04
EP1635839A2 (en) 2006-03-22
US20050038053A1 (en) 2005-02-17
WO2005032527B1 (en) 2005-09-22
BRPI0411295A (pt) 2006-08-01
PL1635839T3 (pl) 2011-02-28
JP2006527226A (ja) 2006-11-30
JP4605800B2 (ja) 2011-01-05
RU2006100033A (ru) 2007-07-20
KR20060054189A (ko) 2006-05-22
SA04250159B1 (ar) 2008-06-21
DE602004028934D1 (de) 2010-10-14
DK1635839T3 (da) 2011-01-03
AU2004277311B2 (en) 2010-04-29
MXPA05012745A (es) 2006-05-17
CN1791412A (zh) 2006-06-21
CA2527617A1 (en) 2005-04-14
IL172316A0 (en) 2011-08-01

Similar Documents

Publication Publication Date Title
NO20060123L (no) Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi
CN101568547B (zh) 作为17βHSD抑制剂的被取代的雌三烯衍生物
DE69113795T2 (de) Steroid 5-alpha-reduktase.
PA8569501A1 (es) Compuestos utiles en terapia
JO2503B1 (en) Benzathiazole derivatives
CA2645343A1 (en) Pyrrolopyrimidine derivatives used as hsp90 inhibitors
ATE432263T1 (de) Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer
K Morrow et al. Recent development of anticancer therapeutics targeting Akt
EP1193250A4 (en) PHENYLSULFAMAT DERIVATIVES
TW200510341A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
Miller et al. Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach
Mastracchio et al. Investigation of biaryl heterocycles as inhibitors of Wee1 kinase
Engström et al. Discovery of USP7 small-molecule allosteric inhibitors
Poirier et al. A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives
NO20060561L (no) Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater
Cichero et al. Exhaustive 3D-QSAR analyses as a computational tool to explore the potency and selectivity profiles of thieno [3, 2-d] pyrimidin-4 (3 H)-one derivatives as PDE7 inhibitors
Sager et al. Homology modeling meets site-directed mutagenesis: An ideal combination to elucidate the topology of 17β-HSD2
WO1999066915A3 (en) Therapeutic applications of estrogenic carboxylic acids
Park et al. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors
Shah et al. Pharmacophore and atom based 3D QSAR studies on the novel 5-alpha-reductase inhibitors
AU2903302A (en) 7-heterocyclyl quinoline and thieno(2,3-b)pyridine derivatives useful as antagonists of gonadotropin releasing hormone
ES2327240T3 (es) Nuevos derivados sustituidos de tiofempirimidinona en calidad de inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
AU2003216084A1 (en) Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
Sobh et al. New thieno [2, 3‐d] pyrimidine derivatives as EGFRWT and EGFRT790M inhibitors: Design, synthesis, antiproliferative activities, docking studies, ADMET, toxicity, MD simulation studies
Reichert et al. Stable expression of human 5α-reductase type II in COS1 cells due to chromosomal gene integration: a novel tool for inhibitor identification

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application